# **Cost-Effectiveness of Endovascular Thrombectomy for Ischemic Stroke in the Japanese Setting**

Y. Morii<sup>1</sup>, K.Sato<sup>2</sup> and D. Kobayashi<sup>3</sup>


1. National Institute of Public Health, Saitama, Japan 2. Nagoya University, Aichi, Japan,

3. Toyama University Hospital, Toyama, Japan

# INTRODUCTION

 $\checkmark$  Endovascular thrombectomy (EVT) for ischemic stroke is highly effective.

- ✓ However, there is a time constraint for EVT, and therefore there are regional disparities in the implementation rates of EVT in Japan like other countries.
- $\checkmark$  While Increasing the implementation rates is a politically important issue,



the cost-effectiveness of EVT in Japan has not been analyzed.

### OBJECTIVE


 $\checkmark$  This study analyzed the cost-effectiveness of EVT in the Japanese setting.

				mRS3-5 utility						
Base case results			acute medical cost							
			chronic medical fee							
	Cost	QALY	ICER				-			
			(US\$/QALY)	0	5000	10000	15000	20000	25000	30000
EVT	31,818	2.32	13,955			ICER(U	IS\$/QA	ALY)		
comparator	26,726	1.95			-	• • •	• -		_	
Δcost	5,092	0.36		Results of sensitivity analysis						

# METHODS

#### Overview of the cost-utility analysis

Subjects	Acute ischemic stroke patients having an indication for EVT (75 years old)		
Targeted technology	EVT + conventional treatment (including t-PA)		
Comparator	Conventional treatment (including t-PA)		
Analysis perspective	Public healthcare payer's perspective (cost inludes direct medical costs)		



Setting	Japanese setting	
Time horizon	10 year after onset	
Indicator	ICER (USD/QALY)*	
Discount rate	2% annually (range 0-4%)	
Models	Decision tree model for 90 days and Markov cohort model for long-term simulation	
Software	R ver 4.1.2	

#### List of parameters

parameters	base case	range	source
Transition probability in Markov model			Morii 2023
Outcome at 90days (initial probabiliry)			
mRSO-2 at 90days at baseline	27.5%	0.15-0.4	Oliveira 2022
mRS6 at 90days at baseline	20.1%	0.1-0.3	Oliveira 2022
risk ratio of functional independence	1.81	1.47-2.22	Oliveira 2022
Utility			
mRS0-2	0.71	0.68-0.74	Xie 2016
mRS3-5	0.31	0.29-0.34	Xie 2016

(Monthly cycle)

#### Analysis model

- A decision tree model was used until 90 days and a Markov cohort model was used for long-term simulation. Health states of modified Rankin Scale (mRS) 0-2 (functional independence), mRS3-5 (severe), and mRS6 (death) were defined.
- ✓ The outcome at 90days was defined from a previous meta-analysis (einstein (São Paulo). 2022;20:1-12)
- ✓ Transition probabilities were obtained from Morii (2023)

(Cost Eff Resour Alloc 21, 12 (2023))

**EE-168** 

#### Database analysis

Analysis of DPC (Diagnosis Procedure Combination / Per-Diem Payment System) data was conducted to estimate acute medical costs

- ✓ Data: data from a DPC database containing about 93% of DPC data in Aichi prefecture (7.5 million population)
- ✓ Subjects: Ischemic stroke patients (n = 2600)

Total medical costs for acute and convalescent hospitalization were aggregated for mRS0-2, mRS3-5, and mRS6 at discharge, respectively.

Direct	medical	cost

acute hospitalization cost	See the box in the right		DPC database	
EVT cost	877500	±20%	National fee table	
chronic medical cost (US\$/month)	19975.25	± 20%	C2H 2020	

mRSO-2 acute cost	2,947,622
mRS3-5 acute cost	3,551,596
mRS6 acute cost	2,520,136

## CONCLUSIONS

✓ The ICER was lower than 5 million JPY/QALY (approximately US\$ 31,631/ QALY), a reference value in Japanese cost-effectiveness analysis, indicating EVT is cost-effective in the Japanese setting. (Results were within the range of previous studies for other countries)







C2H website

Yasuhiro MORII

Center for Outcomes Research and Economic Evaluation for Health (C2H), National Institute of Public Health, Japan

morii.y.aa@niph.go.jp